Global Blood Therapeutics Reports Positive Phase 3 HOPE Study Results

Global Blood Therapeutics, Inc. (GBT) announced its positive top-line Phase 3 clinical trial data on June 27. The results are from Part A of the Phase 3 HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymEmerization) Study to evaluate the use of voxelotor as a treatment for sickle cell disease. On the primary endpoint, patients exhibited a statistically significant increase in hemoglobin levels.


issued an alert at 7:30 am, and the next trade took place for $46.95 at 8:00 am. The stock price exhibited a familiar pattern of spiking on the initial news and then immediately fading back until regular market trading opened at a price of $34. GBT’s stock price pushed higher throughout the day before closing at $44.75, which marks a gain of over 31% from the market open.

Visit the Knowledge Center for more information about clinical trials and how to trade them.

Check out our latest Live Webinar which provides more information about price patterns after clinical trial announcements and how to trade them.

Subscribe here if you would like to start receiving these signals in real-time and start trading!